Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Phase 2 Terminated 46 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is a preliminary proof of efficacy study of AIN457 in patients with bronchial asthma that is poorly controlled with the current standard of care.

Timeline

Start: 2012-03
Primary completion: 2014-11
Completion: 2014-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	10 mg/kg	Intravenous

Safety, Tolerability, and Efficacy of AIN457 in Patients With Uncontrolled Asthma

Summary

Timeline

Drugs

Indications